Angiogenesis Inhibitors and Recurrent Ovarian Cancer
Links shared publicly online about this topic
PARP Inhibitor Improves Survival in Ovarian Cancer
onclive.com — “Olaparib improved median progression-free survival (PFS) by 65% in a phase II trial in women with recurrent ovarian cancer” View full resource at onclive.com
Most Recently Shared on May 18, 2011 at 11:25 pm By:
PARP Inhibitor Improves Survival in Ovarian Cancer http://goo.gl/Rxcz5 #ASCO11
ASCO: PARP Inhibitor Slows Recurrent Ovarian Cancer - QualityPoint Technologies
qualitypointtech.net — “CHICAGO (MedPage Today) -- Treatment with an investigational DNA repair inhibitor almost doubled progression-free survival in patients with relapsed, platinum-sensitive ovarian cancer, data from a randomized trial showed.” View full resource at qualitypointtech.net
Most Recently Shared on May 18, 2011 at 11:45 pm By:
ASCO: PARP Inhibitor Slows Recurrent Ovarian Cancer: CHICAGO (MedPage Today) -- Treatment with an investigational ... http://bit.ly/kWiXXK
Medical News: ASCO: PARP Inhibitor Slows Recurrent Ovarian Cancer - in Meeting Coverage, ASCO from MedPage Today
medpagetoday.com — “CHICAGO -- Treatment with an investigational DNA repair inhibitor almost doubled progression-free survival in patients with relapsed, platinum-sensitive ovarian cancer, data from a randomized trial sh” View full resource at medpagetoday.com
Most Recently Shared on August 29, 2011 at 7:28 pm By:
Roger D. Jones, PhD PhD, Doctor, Health Executive, and Health Social Media
Medical News: ASCO: PARP Inhibitor Slows Recurrent Ovarian Cancer - http://t.co/VTLxRs4 from @medpagetoday #health #medicine
Medical News: SGO: Angiogenesis Inhibitor Scores Split Decision - in Meeting Coverage, SGO from MedPage Today
medpagetoday.com — “SAN FRANCISCO -- An investigational angiogenesis inhibitor produced mixed signals in two small clinical trials involving patients with advanced ovarian cancer.” View full resource at medpagetoday.com
Most Recently Shared on March 22, 2010 at 4:07 pm By:
SGO: Angiogenesis Inhibitor Scores Split Decision (CME/CE) SAN FRANCISCO (MedPage Today) -- An investigational angiog.. http://bit.ly/bXb6a0
ASCO 2011: Maintenance Therapy With PARP Inhibitors Could Play Important Role in Treatment of Recurrent Ovarian Cancer « Libby's H*O*P*E*
healthinfoispower.wordpress.com — “ASCO 2011: Maintenance Therapy With PARP Inhibitors Could Play Important Role in Treatment of Recurrent Ovarian Cancer « Libby's H*O*P*E*” View full resource at healthinfoispower.wordpress.com
Most Recently Shared on May 19, 2011 at 6:04 pm By:
Paul Cacciatore Patient Advocate
ASCO 2011: Maintenance Therapy With PARP Inhibitors Could Play Important Role in Treatment of Recurrent Ovarian Canc… http://wp.me/pcE2v-1zI
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study : The Lancet Oncology
thelancet.com — “Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. By - Pro...” View full resource at thelancet.com
Most Recently Shared on August 21, 2011 at 11:59 pm By:
Michael Fisch Physician, Doctor, Internist, Pain Medicine Physician, and Oncologist
Provocative: PARP inhibitor responses seen in 11 of 46 ovarian #cancer pts without a BRCA mutation (Lancet Oncol), http://ow.ly/68TMe
Therapeutic Response To The Angiogenesis Inhibitor Sunitinib In Ovarian Clear Cell Cancer « Libby's H*O*P*E*
healthinfoispower.wordpress.com — “Therapeutic Response To The Angiogenesis Inhibitor Sunitinib In Ovarian Clear Cell Cancer « Libby's H*O*P*E*” View full resource at healthinfoispower.wordpress.com
Most Recently Shared on March 25, 2011 at 10:57 pm By:
Paul Cacciatore Patient Advocate
Therapeutic Response To The Angiogenesis Inhibitor Sunitinib In Ovarian Clear Cell Cancer http://wp.me/pcE2v-1rS
Medical News: SGO: MicroRNA May Help Predict Ovarian Ca Response - in Meeting Coverage, SGO from MedPage Today
medpagetoday.com — “ORLANDO -- Changes in expression of a microRNA showed potential for predicting response to the angiogenesis inhibitor bevacizumab (Avastin) in recurrent serous ovarian cancer, according to results of” View full resource at medpagetoday.com
Most Recently Shared on March 8, 2011 at 4:25 pm By:
SGO: MicroRNA May Help Predict Ovarian Ca Response (CME/CE) http://bit.ly/hdTEao
Medical News: SGO: MicroRNA May Help Predict Ovarian Ca Response - in Meeting Coverage, SGO from MedPage Today
medpagetoday.com — “ORLANDO -- Changes in expression of a microRNA showed potential for predicting response to the angiogenesis inhibitor bevacizumab (Avastin) in recurrent serous ovarian cancer, according to results of” View full resource at medpagetoday.com
Most Recently Shared on March 8, 2011 at 4:11 pm By:
SGO: MicroRNA May Help Predict Ovarian Ca Response (CME/CE) http://bit.ly/gmDtKs
Medical News: ESMO: Ovarian CA Responds to Bevacizumab - in Meeting Coverage, ESMO from MedPage Today
medpagetoday.com — “MILAN -- Women with high-risk early or advanced ovarian cancer gained almost two months in progression-free survival (PFS) when the angiogenesis inhibitor bevacizumab (Avastin) was added to chemothera” View full resource at medpagetoday.com
Most Recently Shared on October 13, 2010 at 11:09 pm By:
ESMO: Ovarian CA Responds to Bevacizumab (CME/CE) http://bit.ly/cCiyBY
Medical News: ASCO: Drug Shows Promise in Advanced Ovarian Ca - in Meeting Coverage, ASCO from MedPage Today
medpagetoday.com — “CHICAGO -- An investigational angiogenesis inhibitor demonstrated activity in patients with advanced ovarian cancer, irrespective of platinum-sensitivity status, according to data reported here.” View full resource at medpagetoday.com
Most Recently Shared on June 9, 2011 at 5:56 pm By:
ASCO: Drug Shows Promise in Advanced Ovarian Ca http://bit.ly/lT478o
Medical News: ASCO: Drug Shows Promise in Advanced Ovarian Ca - in Meeting Coverage, ASCO from MedPage Today
medpagetoday.com — “CHICAGO -- An investigational angiogenesis inhibitor demonstrated activity in patients with advanced ovarian cancer, irrespective of platinum-sensitivity status, according to data reported here.” View full resource at medpagetoday.com
Most Recently Shared on June 9, 2011 at 6:20 pm By:
ASCO: Drug Shows Promise in Advanced Ovarian Ca: CHICAGO (MedPage Today) -- An… http://goo.gl/fb/N8GSh
Medical News: ASCO: Drug Shows Promise in Advanced Ovarian Ca - in Meeting Coverage, ASCO from MedPage Today
medpagetoday.com — “CHICAGO -- An investigational angiogenesis inhibitor demonstrated activity in patients with advanced ovarian cancer, irrespective of platinum-sensitivity status, according to data reported here.” View full resource at medpagetoday.com
Most Recently Shared on August 29, 2011 at 7:20 pm By:
Roger D. Jones, PhD PhD, Doctor, Health Executive, and Health Social Media
Medical News: ASCO: Drug Shows Promise in Advanced Ovarian Ca - http://t.co/d7KOCOU from @medpagetoday #health #medicine
Oncology Article | Ovarian Neoplasms
mdlinx.com — “IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer” View full resource at mdlinx.com
Most Recently Shared on April 20, 2011 at 12:43 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian cl... http://bit.ly/eDC2te #oncology
Medical News: SGO: GI Risk Clarified for Bevacizumab - in Meeting Coverage, SGO from MedPage Today
medpagetoday.com — “ORLANDO -- Ovarian cancer patients have a twofold greater risk of gastrointestinal adverse effects when bevacizumab is added to chemotherapy, but the angiogenesis inhibitor did not add to other known” View full resource at medpagetoday.com
Most Recently Shared on March 11, 2011 at 9:13 pm By:
SGO: GI Risk Clarified for Bevacizumab (CME/CE) http://bit.ly/gA1glE
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Editor
Editors of Oncology & Biotech News/Oncology Net Guide/OncNurse/Contemporary Oncology, on cancer news from pharma, trials, technology, & more.
-
MedicalFeed
Medical news and updates about medical articles and discussion in Google knols and in many medical websites.
-
Roger D. Jones, PhD
health-care-analytics entrepreneur, physicist, artist
Advertisement
